Anti-cancer drug damages brain vessels

Feb 11, 2008

New research may help explain why an anti-cancer drug causes potentially fatal brain inflammation in certain patients. Scientists at Harvard Medical School mimicked the drug's activity in mice and found that it damaged the cell lining that prevents fluid from leaking from the spinal cord into the brain. The results will be published online on Feb. 11 in the Journal of Experimental Medicine.

The cancer drug Avastin (bevacizumab) is used to treat advanced bowel cancer in combination with chemotherapy. This drug targets a protein called VEGF (vascular endothelial growth factor) that stimulates blood vessel growth. Avastin inhibits the growth of tumors by cutting off their blood supply, which deprives them of oxygen and other nutrients.

In a small percentage of patients, however, Avastin can cause neurological side effects ranging from headaches and blurry vision to potentially fatal seizures and brain swelling.

The new study reveals that VEGF normally protects the specialized cells that create a seal between the brain and spinal column and thus prevent fluid from leaking into the brain. When VEGF was blocked in mice, these cells died and the animals developed brain swelling. The authors suspect that Avastin’s side effects in humans may be caused by a similar phenomenon. Why these symptoms occur in only a few patients is not yet known.

Source: Journal of Experimental Medicine

Explore further: Experts favor US approval of Merck sleeping pill (Update)

add to favorites email to friend print save as pdf

Related Stories

New therapy found for rare lung disorder

Mar 16, 2011

Researchers at the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center have found that the FDA-approved drug sirolimus, used primarily to prevent rejection in organ transplant patients, stabilized ...

Biomarkers predict brain tumor's response to therapy

Jun 23, 2009

A report in Cancer Research, a journal of the American Association for Cancer Research, highlights a new biomarker that may be useful in identifying patients with recurrent glioblastoma, or brain tumors, who would respon ...

Recommended for you

Glaxo, US partnering to develop new antibiotics

17 hours ago

GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.

New sleeping pill poised to hit US markets

May 21, 2013

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Global recommendations on child medicine

May 21, 2013

Transparent information on the evidence supporting global recommendations on paediatric medicines should be easily accessible in order to help policy makers decides on what drugs to include in their national drug lists, according ...

User comments : 0

More news stories

Cold plasma successful against brain cancer cells

For the first time, physicists from the Max Planck Institute for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the synergistic effect of cold atmospheric plasma - a partly ionized ...

Parents can help preteens with abduction concerns

Parents naturally are concerned for their children's safety, particularly when there is news of a child abduction that happens close to home. Finding the balance between emotions and the "teachable moment" as parents talk ...

Weird science: Crystals melt when they're cooled

(Phys.org) —Growing thin films out of nanoparticles in ordered, crystalline sheets, to make anything from microelectronic components to solar cells, would be a boon for materials researchers, but the physics ...

Researchers forward quest for quantum computing

Research teams from UW-Milwaukee and the University of York investigating the properties of ultra-thin films of new materials are helping bring quantum computing one step closer to reality.

Wildlife losses now stabilising

Efforts to conserve biodiversity in the UK, Belgium and Netherlands may be working, despite the widespread perception that wildlife is in terminal decline, a new study suggests.